Literature DB >> 17574687

Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

H Vermeiren1, E Van Craenenbroeck, P Alen, L Bacheler, G Picchio, P Lecocq.   

Abstract

Linear regression modeling on a database of HIV-1 genotypes and phenotypes was applied to predict the HIV-1 resistance phenotype from the viral genotype. In this approach, the phenotypic measurement is estimated as the weighted sum of the effects of individual mutations. Higher order interaction terms (mutation pairs) were included to account for synergistic and antagonistic effects between mutations. The most significant mutations and interactions identified by the linear regression models for 17 approved antiretroviral drugs are reported. Although linear regression modeling is a statistical data-driven technique focused on obtaining the best possible prediction, many of these mutations are also known resistance-associated mutations, indicating that the statistical models largely reflect well characterized biological phenomena. The performance of the models in predicting in vitro susceptibility phenotype and virologic response in treated patients is described. In addition to a high concordance with in vitro measured fold change, which was the primary aim of model design, the models per drug show good predictivity of therapy response for regimens including that drug, even in the absence of other clinically relevant factors such as background regimen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574687     DOI: 10.1016/j.jviromet.2007.05.009

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  47 in total

1.  HIV-1 protease mutations and protease inhibitor cross-resistance.

Authors:  Soo-Yon Rhee; Jonathan Taylor; W Jeffrey Fessel; David Kaufman; William Towner; Paolo Troia; Peter Ruane; James Hellinger; Vivian Shirvani; Andrew Zolopa; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.

Authors:  Kurt Van Baelen; Karl Salzwedel; Evelien Rondelez; Veerle Van Eygen; Stephanie De Vos; Ann Verheyen; Kim Steegen; Yvan Verlinden; Graham P Allaway; Lieven J Stuyver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

Review 3.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

Review 4.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

5.  HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.

Authors:  H R Lapointe; W Dong; G Q Lee; D R Bangsberg; J N Martin; A R Mocello; Y Boum; A Karakas; D Kirkby; A F Y Poon; P R Harrigan; C J Brumme
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

6.  Only slight impact of predicted replicative capacity for therapy response prediction.

Authors:  Hendrik Weisser; André Altmann; Saleta Sierra; Francesca Incardona; Daniel Struck; Anders Sönnerborg; Rolf Kaiser; Maurizio Zazzi; Monika Tschochner; Hauke Walter; Thomas Lengauer
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

7.  Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.

Authors:  Max Lataillade; Jennifer Chiarella; Rong Yang; Steven Schnittman; Victoria Wirtz; Jonathan Uy; Daniel Seekins; Mark Krystal; Marco Mancini; Donnie McGrath; Birgitte Simen; Michael Egholm; Michael Kozal
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

8.  Selecting anti-HIV therapies based on a variety of genomic and clinical factors.

Authors:  Michal Rosen-Zvi; Andre Altmann; Mattia Prosperi; Ehud Aharoni; Hani Neuvirth; Anders Sönnerborg; Eugen Schülter; Daniel Struck; Yardena Peres; Francesca Incardona; Rolf Kaiser; Maurizio Zazzi; Thomas Lengauer
Journal:  Bioinformatics       Date:  2008-07-01       Impact factor: 6.937

9.  Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

Authors:  Michael Neely; Andrea Kovacs
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

10.  Host sequence motifs shared by HIV predict response to antiretroviral therapy.

Authors:  William Dampier; Perry Evans; Lyle Ungar; Aydin Tozeren
Journal:  BMC Med Genomics       Date:  2009-07-23       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.